Activity Description & Educational Objectives
In this activity, two experts discuss the management of atypical hemolytic-uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH), respectively, focusing on the most recent efficacy and safety data on available therapies presented at the latest hematology meeting. Implications of additional clinical data are also explored.
Upon completion of this activity, participants should be better able to:
- Demonstrate knowledge of the rationale for C5 blockade as a management approach in atypical hemolytic-uremic syndrome (aHUS) and the reduction of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH)
- Employ recent efficacy and safety data on available therapies for the treatment of patients with PNH and aHUS in clinical practice
- Assess the implications of recent clinical data pertaining to treatment of patients with PNH and aHUS to improve the long-term outcomes
This activity has been designed to meet the educational needs of nephrologists, hematologists-oncologists, and other clinicians involved in managing hematologic disorders.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: February 28, 2013 - February 27, 2014
Time to Complete: 30 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Larry Greenbaum, MD, PhD
Professor and Division Director
Emory University School of Medicine
Larry Greenbaum, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Alexion Pharmaceuticals, Inc.
Grant/Research Support from Alexion Pharmaceuticals, Inc.
Catherine Broome, MD
Division of Hematology/Oncology
Department of Medicine and Lombardi Comprehensive Cancer Center
Georgetown University Hospital
Catherine Broome, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Alexion Pharmaceuticals, Inc.
Marc S. Zumberg, MD
Division of Hematology/Oncology
Department of Medicine
University of Florida College of Medicine
Marc S. Zumberg, MD, currently has no financial interests/relationships or affiliations in relation to this activity.
Regina Janesko, MS
PVI, PeerView Institute for Medical Education
Regina Janesko, MS, currently has no financial interests/relationships or affiliations in relation to this activity.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly sponsored by the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an unrestricted educational grant from
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.